SCHEMBL3008323

SCHEMBL3008323

O=S(=O)(c1ccc(F)cc1Cl)C1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.52
L3MBTL1 Q9Y468 4/20 0.52
ALDH1A1 P00352 3/20 0.52
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
CTSS P25774 4/20 0.50
MAPK1 P28482 4/20 0.50
AR P10275 3/20 0.48
MAPT P10636 5/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP3A4 P08684 1/20 0.45
FFAR2 O15552 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011275 0.93 CTSS (0.51) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3014430 0.92 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3019490 0.92 CTSS (0.49) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3017539 0.92 CTSS (0.49) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3008103 0.92 SMN1; SMN2 (0.51) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3013324 0.92 CTSS (0.52) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3002467 0.92 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3018181 0.91 AR (0.53) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3008195 0.91 CTSS (0.51) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL3008815 0.90 CTSS (0.49) SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.